Hemodynamics, fluids & transfusion
Anti-inflammatory therapies are associated with delayed onset of anemia and reduction in transfusion requirements in critically ill patients: results from two studies
Authors' conclusion
Immunomodulatory treatment was associated with a slower decline in Hb level in critically ill patients with COVID-19 and with less transfusion.
Study context
- Population
- Critically ill patients with hypoxemic respiratory failure due to COVID-19observational cohort n = 772
- Comparison
- Steroids or steroids plus IL-6 blocking agents vs no treatment
- Outcome
- Trajectory of Hb decline and need for red blood cell (RBC) transfusions
Methodological detailsmultivariate modeling, validation cohort (subset of REMAP-CAP)
- Multivariate modeling
- Validation cohort (subset of REMAP-CAP)
Performance
As reported in the abstract
Hb level and RBC transfusions
- Hemoglobin (Hb) higher in treated groups vs untreated at all time points (both cohorts)
- Incidence and number of transfused patients lower with combination treatment vs untreated (observational cohort)
- Multivariate analysis (adjusted for baseline Hb imbalance and mechanical ventilation): steroids associated with slower Hb decline; combination treatment associated with slower Hb decline and less transfusions
- Results the same in validation cohort
Original publication
Anti-inflammatory therapies are associated with delayed onset of anemia and reduction in transfusion requirements in critically ill patients: results from two studies. Crit Care. Published 9 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →